Luoyang Central Hospital Affiliated to Zhengzhou University, Department of Neurosurgery, Luoyang, China.
Turk Neurosurg. 2024;34(3):401-406. doi: 10.5137/1019-5149.JTN.41647-22.1.
To analyze the efficacy of surgical resection versus brain biopsy combined with postoperative chemotherapy for primary central nervous system lymphoma (PCNSL) and to discuss a clinically standardized treatment protocol.
Patients with a pathological diagnosis of PCNSL and subsequent chemotherapy between 2016 and 2021 at Northern Jiangsu People?s Hospital were selected and divided into groups according to whether they underwent microsurgical resection or stereotactic needle biopsy. Statistical analyses were performed to compare efficacy and safety in the two groups.
A total of 21 patients with PCNSL were identified, of whom 12 underwent resection and 9 underwent diagnostic stereotactic biopsy only. Compared with the resection group, the biopsy group had a higher proportion of deep tumors (55.6% vs. 8.3%, p=0.016), and the mean intraoperative bleeding was significantly reduced (13.33 ± 6.61 mL vs. 170.83 ± 101.04 ml, p < 0.001). In addition, the mean survival time of patients who died during the postoperative follow-up period was shorter (6.83 ± 1.60 vs. 18.56 ± 10.20 months, p=0.016), and the one-year survival rate was lower (33.3% vs. 83.3%, p=0.032). There was no significant difference between the two groups in terms of the mean progression-free survival time or new functional impairment after surgery.
For PCNSL, patients who undergo surgical resection have a better outcome than those who undergo biopsy only, suggesting that when the tumor is located at a surgically resectable site, surgical resection should be actively chosen; when the tumor is located at a deep and unresectable site, brain biopsy should be chosen.
分析手术切除与脑活检联合术后化疗治疗原发性中枢神经系统淋巴瘤(PCNSL)的疗效,并探讨一种临床规范化治疗方案。
选取 2016 年至 2021 年在苏北人民医院接受病理诊断为 PCNSL 并随后接受化疗的患者,根据是否接受显微镜手术切除或立体定向针活检分为两组。对两组患者的疗效和安全性进行统计学分析。
共纳入 21 例 PCNSL 患者,其中 12 例行切除术,9 例行诊断性立体定向活检。与切除术组相比,活检组深部肿瘤比例较高(55.6%比 8.3%,p=0.016),术中出血量明显减少(13.33±6.61ml 比 170.83±101.04ml,p<0.001)。此外,术后随访期间死亡患者的平均生存时间更短(6.83±1.60 比 18.56±10.20 个月,p=0.016),一年生存率更低(33.3%比 83.3%,p=0.032)。两组患者的平均无进展生存时间或术后新的功能障碍无显著差异。
对于 PCNSL,接受手术切除的患者比仅接受活检的患者预后更好,提示当肿瘤位于可手术切除部位时,应积极选择手术切除;当肿瘤位于深部且不可切除部位时,应选择脑活检。